Lower respiratory tract disease in Thoroughbred racehorses: analysis of endoscopic data from a UK training yard.
BACKGROUND
There has been much research directed at potential causative agents and the epidemiology of lower respiratory tract disease (LRTD), but few reports of the clinical progression and outcome.


OBJECTIVE
To define clinical features of LRTD in racehorses, including association with age and average duration of disease, through the analysis of endoscopic data.


METHODS
A retrospective analysis of records from a single training yard of endoscopic examinations undertaken over a 2-year period was performed. Horses were subjected to regular endoscopic examination for a variety of reasons, and all horses placed on antibiotic therapy for lower respiratory tract disease were rescoped following treatment. Data analysed included a 0-8 tracheal mucus score based on visible endoscopic mucus and gross tracheal lavage turbidity, as well as age and treatment duration and type.


RESULTS
A total of 522 endoscopic examinations undertaken on 123 horses and tracking 169 episodes of lower respiratory tract disease were recorded. Mean duration of disease episode was 15.5 days (median = 11 days, range = 4-61 days). Horses age 2 years were significantly more likely than those age > or=3 years to have at least one episode of respiratory disease (P<0.001). There was a direct association between initial tracheal mucus score and rescope score after treatment.


CONCLUSIONS
Lower respiratory tract disease was more common in 2-year-olds than in older horses. Affected horses had endoscopic evidence of increased tracheal mucus accumulation for an average of 15.5 days per episode, a considerably shorter period than that suggested by previous studies.


CONCLUSIONS
Endoscopic examinations permit longitudinal tracking of lower respiratory tract disease in Thoroughbred racehorses. A prolonged duration of disease, sometimes extending for months, can be expected in a small proportion of cases, some of which appear to be refractory to treatment. There is a clear need for evidence-based analysis of treatment regimes to assist clinicians in decision making when managing disease in both individual and group situations.
Ramzan
P H L
PH
Rossdale and Partners, Beaufort Cottage Stables, High Street, Newmarket, Suffolk, UK.
Parkin
T D H
TD
Shepherd
M C
MC
D000367:Age Factors; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D018450:Disease Progression; D004724:Endoscopy / Q000379:methods / Q000662:veterinary; D005260:Female; D006734:Horse Diseases / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology; D006736:Horses; D008297:Male; D009093:Mucus / Q000378:metabolism*; D010805:Physical Conditioning, Animal / Q000009:adverse effects / Q000502:physiology; D012140:Respiratory Tract Diseases / Q000188:drug therapy / Q000473:pathology / Q000503:physiopathology / Q000662:veterinary*; D012189:Retrospective Studies; D012307:Risk Factors; D013177:Sports; D013997:Time Factors; D014132:Trachea / Q000473:pathology*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents